Margaret Hills

3.7k citations

41 papers · 2.4k indexed · h-index 22

Oncology top 2%
Cancer Research top 1%
Molecular Biology top 10%
Genetics top 2%
Pulmonary and Respiratory Medicine top 10%

Co-authors: Mitch Dowsett Janine Salter Ian E. Smith Simone Detre J. Michael Dixon Anthony Skene Roger A’Hern Geraldine Walsh
Topics: HER2/EGFR in Cancer Research (26 papers)Breast Cancer Treatment Studies (19 papers)Estrogen and related hormone effects (18 papers)
Cited by: Cancer Research Oncology Genetics
Journals: Journal of Clinical Oncology JNCI Journal of the National Cancer Institute Cancer Research
Partner nations: United Kingdom United States France

In The Last Decade

Margaret Hills

41 papers receiving 2.4k citations

Peers

Countries citing papers authored by Margaret Hills

Since Specialization

Citations

This map shows the geographic impact of Margaret Hills's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Margaret Hills with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Margaret Hills more than expected).

Fields of papers citing papers by Margaret Hills

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Margaret Hills. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Margaret Hills. The network helps show where Margaret Hills may publish in the future.

Co-authorship network of co-authors of Margaret Hills

This figure shows the co-authorship network connecting the top 25 collaborators of Margaret Hills. A scholar is included among the top collaborators of Margaret Hills based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Margaret Hills. Margaret Hills is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Clinico-pathologic relationships with Ki67 and its change with short-term aromatase inhibitor treatment in primary ER + breast cancer: further results from the POETIC trial (CRUK/07/015) 2023 ·Breast Cancer Research ·Judith M. Bliss,Holly Tovey,Abigail Evans,Chris Holcombe,Kieran Horgan,Elizabeth Mallon,Raghavan Vidya,Anthony Skene,Andrew Dodson,Margaret Hills,Simone Detre,Lila Zabaglo,Jane Banerji,Lucy Kilburn,James P. Morden,J.F.R. Robertson,Ian Smith,Mitch Dowsett,(unknown)	6
2	Relationship between ER expression by IHC or mRNA with Ki67 response to aromatase inhibition: a POETIC study 2022 ·Breast Cancer Research ·Elena López‐Knowles,Simone Detre,Margaret Hills,Eugene F. Schuster,Maggie C.U. Cheang,Holly Tovey,Lucy Kilburn,Judith M. Bliss,J.F.R. Robertson,Elizabeth Mallon,Anthony Skene,Abigail Evans,Ian Smith,Mitch Dowsett	5
3	Combination of mTORC1/2 inhibitor vistusertib plus fulvestrant in vitro and in vivo targets oestrogen receptor-positive endocrine-resistant breast cancer 2019 ·Breast Cancer Research ·Sunil Pancholi,Mariana Ferreira Leal,Ricardo Ribas,Nikiana Simigdala,Eugene F. Schuster,Sophie Château‐Joubert,Lila Zabaglo,Margaret Hills,Andrew Dodson,Qiong Gao,Stephen Johnston,Mitch Dowsett,Sabina Cosulich,(unknown),Lesley‐Ann Martin	12
4	Association of p27 and Cyclin D1 Expression and Benefit from Adjuvant Trastuzumab Treatment in HER2-Positive Early Breast Cancer: A TransHERA Study 2018 ·Clinical Cancer Research ·Martin Filipits,Urania Dafni,Michael Gnant,Varvara Polydoropoulou,Margaret Hills,Astrid Kiermaier,Evandro de Azambuja,Denis Larsimont,Federico Rojo,Giuseppe Viale,Masakazu Toi,Nadia Harbeck,(unknown),Richard D. Gelber,Phuong Dinh,Dimitrios Zardavas,Brian Leyland‐Jones,Martine Piccart,Mitch Dowsett	15
5	Relationship between IHC4 score and response to neo-adjuvant chemotherapy in estrogen receptor-positive breast cancer 2017 ·Breast Cancer Research and Treatment ·Amna Sheri,Ian E. Smith,Margaret Hills,Robin L. Jones,Stephen Johnston,Mitch Dowsett	10
6	Principal results of the cancer of the ovary abiraterone trial (CORAL): A phase II study of abiraterone in patients with recurrent epithelial ovarian cancer (CRUKE/12/052) 2016 ·Annals of Oncology ·Susana Banerjee,Lucy Kilburn,Rebecca Bowen,Holly Tovey,Marcia Hall,Stan B. Kaye,Gordon Rustin,Martin Gore,Jennifer McLachlan,Ayoma D. Attygalle,Nina Tunariu,João Paulo da Silveira Nogueira Lima,Peter Chatfield,(unknown),Elizabeth Folkerd,Margaret Hills,Sophie Perry,Gerhardt Attard,Mitch Dowsett,Judith M. Bliss	2
7	Case report: A rare case of eosinophilic cholecystitis presenting after talc pleurodesis for recurrent pneumothorax 2016 ·Respiratory Medicine Case Reports ·(unknown),Mark L. Jordan,Margaret Hills	2
8	Heterogeneity in global gene expression profiles between biopsy specimens taken peri-surgically from primary ER-positive breast carcinomas 2016 ·Breast Cancer Research ·(unknown),Elena López‐Knowles,Qiong Gao,Maggie C.U. Cheang,James P. Morden,Joel S. Parker,Lesley‐Ann Martin,(unknown),Fiona E. McNeill,Margaret Hills,Simone Detre,Maria Afentakis,Lila Zabaglo,Andrew Dodson,Anthony Skene,Chris Holcombe,J.F.R. Robertson,A. Ian Smith,Judith M. Bliss,Mitch Dowsett	20
9	Clinical utility of the IHC4+C score in oestrogen receptor-positive early breast cancer: a prospective decision impact study 2015 ·British Journal of Cancer ·Belinda Yeo,Lila Zabaglo,Margaret Hills,Andrew Dodson,Ian Smith,Mitch Dowsett	33
10	Biomarker changes associated with the development of resistance to aromatase inhibitors (AIs) in estrogen receptor-positive breast cancer 2014 ·Annals of Oncology ·Mónica Arnedos,(unknown),Maria Afentakis,Roger A’Hern,Margaret Hills,Janine Salter,I. E. Smith,Jorge S. Reis‐Filho,Mitch Dowsett	30
11	Residual proliferative cancer burden to predict long-term outcome following neoadjuvant chemotherapy 2014 ·Annals of Oncology ·Amna Sheri,Ian E. Smith,Stephen Johnston,Roger A’Hern,Ashutosh Nerurkar,Robin L. Jones,Margaret Hills,Simone Detre,Sarah E. Pinder,W. Fraser Symmans,Mitch Dowsett	78
12	Assessment of the contribution of the IHC4+C score to decision making in clinical practice in early breast cancer 2012 ·British Journal of Cancer ·Sarah Barton,Lila Zabaglo,Roger A’Hern,Nicholas C. Turner,Thomas Ferguson,Suzanne C. O’Neill,Margaret Hills,Ian Smith,Mitch Dowsett	50
13	ER and HER2 expression are positively correlated in HER2 non-overexpressing breast cancer 2012 ·Breast Cancer Research ·(unknown),Margaret Hills,Suzanne Drury,Janine Salter,G. Sumo,Roger A’Hern,Judith M. Bliss,Ivana Šestak,Jack Cuzick,Peter Barrett‐Lee,Adrian L. Harris,Mitch Dowsett,(unknown)	49
14	A Marker of Homologous Recombination Predicts Pathologic Complete Response to Neoadjuvant Chemotherapy in Primary Breast Cancer 2010 ·Clinical Cancer Research ·Monika Graeser,Afshan McCarthy,Christopher J. Lord,Kay Savage,Margaret Hills,Janine Salter,Nick Orr,Marina Parton,Ian E. Smith,Jorge S. Reis‐Filho,Mitch Dowsett,Alan Ashworth,Nicholas C. Turner	222
15	Prognostic Value of Ki67 Expression After Short-Term Presurgical Endocrine Therapy for Primary Breast Cancer 2007 ·JNCI Journal of the National Cancer Institute ·Mitch Dowsett,Ian E. Smith,S. Ebbs,J. Michael Dixon,Anthony Skene,Roger A’Hern,Janine Salter,Simone Detre,Margaret Hills,Geraldine Walsh	469
16	Biomarker Changes During Neoadjuvant Anastrozole, Tamoxifen, or the Combination: Influence of Hormonal Status and HER-2 in Breast Cancer—A Study from the IMPACT Trialists 2005 ·Journal of Clinical Oncology ·Mitch Dowsett,(unknown),J. Michael Dixon,Anthony Skene,C.D.M. Griffith,Irene Boeddinghaus,Janine Salter,Simone Detre,Margaret Hills,S. Ashley,Stephen Francis,Geraldine Walsh,Ian E. Smith	229
17	Growth factor signalling and response to endocrine therapy: the Royal Marsden Experience 2005 ·Endocrine Related Cancer ·M Dowsett,S. Johnston,(unknown),Janine Salter,Margaret Hills,Simone Detre,M. Cristina Gutiérrez,S K Mohsin,Jianzhong Shou,D. Craig Allred,Rachel Schiff,C. K. Osborne,I. E. Smith	33
18	Anastrozole demonstrates clinical and biological effectiveness in oestrogen receptor-positive breast cancers, irrespective of the erbB2 status 2004 ·European Journal of Cancer ·J. Michael Dixon,(unknown),Margaret Hills,Lorna Renshaw,David Cameron,Thomas Anderson,William R. Miller,Mitch Dowsett	32
19	Correlation between cyclooxygenase-2 expression and angiogenesis in human breast cancer. 2003 ·PubMed ·Giles Davies,Janine Salter,Margaret Hills,Lesley‐Ann Martin,Nigel Sacks,Mitch Dowsett	111
20	HER-2 amplification impedes the antiproliferative effects of hormone therapy in estrogen receptor-positive primary breast cancer. 2001 ·PubMed ·Mitch Dowsett,Catherine Harper‐Wynne,Irene Boeddinghaus,Janine Salter,Margaret Hills,Mike J. Dixon,(unknown),G P Gui,N Sacks,I. E. Smith	150

About Margaret Hills

Margaret Hills is a scholar working on Cancer Research, Oncology and Genetics, having authored 41 papers that have together received 2.4k indexed citations. Recurring topics across this work include HER2/EGFR in Cancer Research (26 papers), Breast Cancer Treatment Studies (19 papers) and Estrogen and related hormone effects (18 papers). The work is most often cited by research in Cancer Research (1.4k citations), Oncology (1.6k citations) and Genetics (772 citations). Margaret Hills has collaborated with scholars based in United Kingdom, United States and France. Frequent co-authors include Mitch Dowsett, Janine Salter, Ian E. Smith, Simone Detre, J. Michael Dixon, Anthony Skene, Roger A’Hern, Geraldine Walsh, Irene Boeddinghaus and S. Ebbs. Their work appears in journals such as Journal of Clinical Oncology, JNCI Journal of the National Cancer Institute and Cancer Research.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact